LU-31130

Identification

LU-31130 is a rapid acting therapy developed by H. Lundbeck A/S to treat Psychosis, Schizophrenia and Schizoaffective Disorders. It acts at the Dopamine D4 receptors in the cortex and has low affinity for D2 receptors, adrenoceptors, muscarinic and histaminergic receptors.
It provides anti-psychotic characteristic and a low incidence of extrapyramidal and cardiovascular side effects.

Synonyms

Not Available

Categories

Not Available

UNII

Not Available

CAS number

Not Available

Weight

Not Available

Chemical Formula

Not Available

InChI Key

Not Available

InChI

Not Available

IUPAC Name

Not Available

SMILES

Not Available

Pharmacology

Indication

Investigated for use/treatment in psychosis and schizophrenia and schizoaffective disorders.

Pharmacodynamics

Not Available

Mechanism of action

Not Available

Unlock Additional Data

Additional Data Available

Adverse Effects

Comprehensive structured data on known drug adverse effects with statistical prevalence. MedDRA and ICD10 ids are provided for adverse effect conditions and symptoms.

Structured data covering drug contraindications. Each contraindication describes a scenario in which the drug is not to be used. Includes restrictions on co-administration, contraindicated populations, and more.